Global Information
회사소개 | 문의

폐동맥 고혈압 : 파이프라인 리뷰

Pulmonary Arterial Hypertension - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 08월 상품 코드 213126
페이지 정보 영문 269 Pages
가격
US $ 2,000 ₩ 2,272,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,545,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,818,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


폐동맥 고혈압 : 파이프라인 리뷰 Pulmonary Arterial Hypertension - Pipeline Review, H2 2018
발행일 : 2018년 08월 페이지 정보 : 영문 269 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

폐동맥 고혈압이란 폐동맥(심장으로부터 폐로 산소 흡입용 혈액을 보내는 동맥) 내부의 혈압이 상승하는 질환입니다. 주요 증상은 가슴 진통, 권태감, 실신 발작, 발목·다리 부종 등입니다. 위험요인으로는 가족력, 연령, 비만, 폐쇄성 수면 무호흡증(OSA) 외에 선천성 심질환, 폐병, 간장병, 경피증, 붉은 반점성 낭창 등 결합조직계 장애 등의 질환이 있습니다. 주요 치료제는 실데나필, 프로스타노이드, 칼슘 채널 차단제 등입니다.

세계 각국에서의 폐동맥 고혈압증(PAH: Pulmonary Arterial Hypertension) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 최신 동향, 임상시험 단계별 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

폐동맥 고혈압 개요

치료제 개발

  • 폐동맥 고혈압용 파이프라인 제품 : 개요
  • 기업별 폐동맥 고혈압 치료제
  • 대학/연구기관별 폐동맥 고혈압 치료제
  • 폐동맥 고혈압 치료제 : 개발중인 제품 목록(기업별)
  • 폐동맥 고혈압 치료제 : 연구중인 제품 목록(대학/연구기관별)

폐동맥 고혈압 : 치료제 평가

  • 표적별
  • 작용기전별
  • 투여 방법별
  • 분자 종류별

폐동맥 고혈압 치료제 개발 참여 기업

  • Actelion Ltd
  • Aerogen Ltd.
  • Arena Pharmaceuticals Inc
  • Ascendis Pharma A/S
  • Asklepion Pharmaceuticals LLC
  • AVEO Pharmaceuticals Inc
  • Bial - Portela & Ca SA
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Camurus AB
  • Capricor Therapeutics Inc
  • Celsion Corp
  • Celtaxsys Inc
  • Chiesi Farmaceutici SpA
  • Chugai Pharmaceutical Co Ltd
  • Complexa Inc
  • Eli Lilly and Company
  • Galectin Therapeutics Inc
  • GlaxoSmithKline Plc
  • HitGen LTD.
  • Insmed Inc.
  • Insys Therapeutics Inc
  • Johnson & Johnson
  • Liquidia Technologies Inc
  • MannKind Corp
  • Mezzion Pharma Co Ltd
  • Nippon Kayaku Co Ltd
  • Nippon Shinyaku Co Ltd
  • Nissan Chemical Industries Ltd
  • Northern Therapeutics Inc
  • Novartis AG.
  • Peloton Therapeutics Inc
  • PhaseBio Pharmaceuticals Inc
  • Pluristem Therapeutics Inc
  • Polyphor Ltd.
  • Pulmokine Inc
  • Reata Pharmaceuticals Inc
  • Respira Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • Savara Inc.
  • Serodus ASA
  • Silence Therapeutics Plc
  • SteadyMed Therapeutics Inc
  • Suda Ltd.
  • Nissan Chemical Industries Ltd
  • Toray Industries Inc
  • United Therapeutics Corp
  • Vicore Pharma AB
  • Vivus Inc

약제 프로파일

폐동맥 고혈압 치료제 : 개발 휴지 상태인 제품

폐동맥 고혈압 치료제 : 개발이 중지된 제품

폐동맥 고혈압 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향과 프레스 릴리스

부록

도표

LSH 17.09.19

List of Tables

  • Number of Products under Development for Pulmonary Arterial Hypertension, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Acceleron Pharma Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Aerogen Ltd, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Bayer AG, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Biogen Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Bristol-Myers Squibb Co, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Camurus AB, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Capricor Therapeutics Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Complexa Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Denovo Biopharma LLC, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Co, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Insmed Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Insys Therapeutics Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Japan Tobacco Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Liquidia Technologies Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by MannKind Corp, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Nissan Chemical Industries Ltd, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Northern Therapeutics Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Pulmokine Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Relief Therapeutics Holding AG, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Roivant Sciences Ltd, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Serodus ASA, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Suda Pharmaceuticals Ltd, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Toray Industries Inc, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corp, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Vicore Pharma AB, H2 2018
  • Pulmonary Arterial Hypertension - Pipeline by Vivus Inc, H2 2018
  • Pulmonary Arterial Hypertension - Dormant Projects, H2 2018
  • Pulmonary Arterial Hypertension - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Pulmonary Arterial Hypertension, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2018, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 9, 11, 20, 35, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 4 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Pulmonary Arterial Hypertension - Overview
  • Pulmonary Arterial Hypertension - Therapeutics Development
  • Pulmonary Arterial Hypertension - Therapeutics Assessment
  • Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
  • Pulmonary Arterial Hypertension - Drug Profiles
  • Pulmonary Arterial Hypertension - Dormant Projects
  • Pulmonary Arterial Hypertension - Discontinued Products
  • Pulmonary Arterial Hypertension - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research